Harmony Biosciences Holdings, Inc. logo HRMY - Harmony Biosciences Holdings, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 8
HOLD 3
SELL 2
STRONG
SELL 0
| PRICE TARGET: $44.00 DETAILS
HIGH: $50.00
LOW: $36.00
MEDIAN: $46.00
CONSENSUS: $44.00
UPSIDE: 15.99%

Stock News

Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting

Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that six abstracts in narcolepsy and idiopathic hypersomnia have been accepted for poster presentation at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), which will be held June 14 – 17 in Baltimore, MD. The poster presentation details are as follows: Abstract Title Poster Presentation Session Treatment with Pitolisant in Subgroups of Adults with.

Jun 11, 2026 04:05 AM • businesswire.com
Harmony Biosciences to Participate in Upcoming Investor Conferences

Harmony Biosciences to Participate in Upcoming Investor Conferences

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences. Goldman Sachs 47th Annual Global Healthcare Conference Fireside Chat: June 9, 2026, at 8:40 a.m. ET Location: Miami, FL Oppenheimer CNS & Neuro-Muscular Summit Fireside Chat: June 10, 2026, at 3:25 p.m. ET Location: Miami, FL A webcast of the fireside chats will be available on the investor.

May 27, 2026 04:05 AM • businesswire.com
Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities

Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today reported Q1 2026 revenue of $215.4 million, delivering 17% year‑over‑year growth for WAKIX®. Performance during the quarter reflected continued strong demand, offset by market access headwinds observed every Q1, which were more pronounced this year. This follows the strongest three consecutive quarters in franchise history, and the Company reinforced 2026 full year revenue guidance. The Company also.

May 07, 2026 03:30 AM • businesswire.com
Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on May 7, 2026, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-274-8461 (domestic) or 203-518-9814 (international or alternate), and reference passcode HRMYQ126. It is recommende.

Apr 23, 2026 04:05 AM • businesswire.com
Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting

Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore open-label extension data from the company's investigation of EPX-100 (clemizole hydrochloride) in the ongoing Phase 3 ARGUS trial for the treatment of Dravet syndrome at the 2026 American Academy of Neurology Annual Meeting being held April 18 – 22 in Chicago, IL. The ARGUS trial is currently enrolling, and more information about the trial can be found at argust.

Apr 16, 2026 04:05 AM • businesswire.com
Harmony Biosciences Eyes $1B WAKIX Runway, Teases 2026 Pipeline Catalysts at Needham Conference

Harmony Biosciences Eyes $1B WAKIX Runway, Teases 2026 Pipeline Catalysts at Needham Conference

Harmony Biosciences (NASDAQ: HRMY) executives outlined 2026 priorities at Needham and Company's Virtual Healthcare Conference, emphasizing continued growth for WAKIX and multiple late-stage pipeline readouts across sleep-wake and rare epilepsy indications. WAKIX outlook and commercial execution President and CEO Jeffrey Dayno said Harmony is "on track to achieve over $1 billion in net revenue for WAKIX

Apr 14, 2026 11:35 PM • defenseworld.net
Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer

Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced the appointment of Glenn Reicin as Chief Financial Officer, effective immediately, supporting Harmony's continued focus on strategic growth, financial strength, and long‑term value creation. Harmony is also reiterating its 2026 net product revenue guidance of $1.0 to $1.04 billion. Mr. Reicin is a seasoned biopharmaceutical executive with extensive experience across publicly traded and pri.

Apr 14, 2026 04:05 AM • businesswire.com
Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board

Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the appointment of Peter Anastasiou as Chief Operating Officer and updates to its Board of Directors, including the appointment of Troy Ignelzi as a director and the nomination of Geno J. Germano as a director for election at Harmony's 2026 Annual Meeting of Shareholders. Mr. Anastasiou previously served on Harmony Biosciences' Board of Directors, where he contributed strategic insight acro.

Apr 02, 2026 04:05 AM • businesswire.com

Price Targets